FDA Approves Wezlana for Multiple Inflammatory Diseases

THURSDAY, Nov. 2, 2023 -- The U.S. Food and Drug Administration has approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases. 
The approval includes indications...